Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:20:36 2024-07-12 pm EDT			5-day change	1st Jan Change
11.71 ^USD	+1.83%		+3.72%	+73.87%

Jul. 10	Amylyx Pharmaceuticals Acquires Avexitide From Eiger BioPharmaceuticals for $35 Million	MT
Jul. 09	Spruce Biosciences, Inc. completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	CI

Eiger Biopharmaceuticals, Inc. Announces Initiation of Enrollment and First Patient Dosed in LOWR HDV – 4 in Hannover, Germany

January 06, 2016 at 08:00 am EST

Eiger BioPharmaceuticals, Inc. announced the initiation of enrollment and first patient dosed in LOWR HDV – 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 4) at the Hannover Medical School in Hannover, Germany. LOWR HDV – 4 is an open label, dose titration study designed to evaluate the efficacy and tolerability of lonafarnib combined with ritonavir for a total of 24 weeks in fifteen patients with chronic hepatitis delta.

Latest news about Eiger BioPharmaceuticals, Inc.

Amylyx Pharmaceuticals Acquires Avexitide From Eiger BioPharmaceuticals for $35 Million	Jul. 10	MT
Spruce Biosciences, Inc. completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	Jul. 08	CI
Moshe Arkin Engages with Eiger BioPharmaceuticals	Jul. 01	CI
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar	Jun. 21	RE
Spruce Biosciences, Inc. stalking horse asset purchase agreement to acquire Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	Jun. 13	CI
Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.	May. 07	CI
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug	May. 06	MT
Eiger Biopharmaceuticals, Inc. Announces Resignation of William G. Kachioff as Chief Financial Officer	May. 02	CI
Eiger Biopharmaceuticals, Inc. Appoints Douglas Staut to Serve as the Company's Chief Restructuring Officer	May. 02	CI
Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.	Apr. 24	CI
Selection of Successful Bidder Filed by Eiger BioPharmaceuticals, Inc.	Apr. 19	CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index	Apr. 09	CI
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Bidding Procedure Approved for Eiger BioPharmaceuticals, Inc.	Apr. 05	CI
Motion for Joint Administration Approved for Eiger BioPharmaceuticals, Inc.	Apr. 05	CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from S&P TMI Index	Apr. 03	CI
Eiger BioPharmaceuticals, Inc. Announces Resignation of Jeffrey S. Glenn as Member of the Board of Directors	Apr. 03	CI
Health Care Down as Obesity-Drug Optimism Fades -- Health Care Roundup	Apr. 01	DJ
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
Top Midday Decliners	Apr. 01	MT
Sector Update: Health Care	Apr. 01	MT
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection; Shares Fall	Apr. 01	MT
Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	Apr. 01	CI
Motion for Joint Administration Filed by Eiger BioPharmaceuticals, Inc.	Apr. 01	CI
Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy	Apr. 01	CI

Chart Eiger BioPharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EIGER BIOPHARMACEUTICALS, INC.	+73.87%	17.34M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+47.58%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research